More on BMY

- Summary
- Chart
- Profile
- Historical


- Earnings (-22.2% Growth)
- Ratings (4.8 Score)
- Holders
- Dividends (2.5% Yield)
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (10/27/15)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

BMY Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 4.2B
Marketable securities 1.28B
Receivables 3.67B
Inventories 1.3B
Deferred income taxes 1.89B
Prepaid expenses and other 502M
Total Current Assets 13.06B
Property, plant and equipment 4.36B
Goodwill 6.98B
Other intangible assets 1.56B
Deferred income taxes 577M
Marketable securities 4.63B
Other assets 787M
Total Assets 31.95B
Current Liabilities:
Short-term borrowings 755M
Accounts payable 1.84B
Accrued expenses 2.1B
Deferred income 939M
Accrued rebates and returns 1.07B
U.S. and foreign income taxes payable 98M
Dividends payable 634M
Total Current Liabilities 7.44B
Pension, postretirement, and postemployment liabilities 727M
Deferred income 667M
U.S. and foreign income taxes payable 744M
Other liabilities 475M
Long-term debt 6.62B
Total Liabilities 16.66B
Commitments and contingencies (Note 14) 0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 221M
Capital in excess of par value of stock 1.36B
Accumulated other comprehensive loss -2.17B
Retained earnings 32.36B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010 -16.65B
Total Bristol-Myers Squibb Company Shareholders' Equity 15.12B
Noncontrolling interest 168M
Total Equity 15.29B
Total Liabilities and Equity 31.95B